Immuneering Corporation: Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + …

Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard ...

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard ...

Economic growth in FY26 estimated at 7.4%

According to data released by National Statistics Office (NSO), services sector estimated to grow by 9.1 per cent in FY26, ...

What People Are Getting Wrong This Week: Is the World Ending in 2026?

A 1960 science paper predicted humanity would be crushed by overpopulation on Friday, Nov. 13, 2026. What it got right—and ...